0.35
前日終値:
$0.3725
開ける:
$0.364
24時間の取引高:
3.18M
Relative Volume:
1.58
時価総額:
$84.91M
収益:
$9.10M
当期純損益:
$-82.47M
株価収益率:
-0.6034
EPS:
-0.58
ネットキャッシュフロー:
$-72.32M
1週間 パフォーマンス:
-24.65%
1か月 パフォーマンス:
-31.28%
6か月 パフォーマンス:
-59.41%
1年 パフォーマンス:
-71.77%
Vaxart Inc Stock (VXRT) Company Profile
名前
Vaxart Inc
セクター
電話
(650) 550-3500
住所
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
VXRT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
VXRT
Vaxart Inc
|
0.35 | 84.91M | 9.10M | -82.47M | -72.32M | -0.58 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-08-15 | 開始されました | Oppenheimer | Outperform |
2021-12-29 | 再開されました | Jefferies | Buy |
2021-11-02 | 開始されました | Cantor Fitzgerald | Overweight |
2021-06-29 | ダウングレード | B. Riley Securities | Buy → Neutral |
2021-06-24 | 開始されました | Jefferies | Buy |
2021-06-11 | 開始されました | Piper Sandler | Overweight |
2020-08-12 | 繰り返されました | H.C. Wainwright | Buy |
2020-07-13 | 開始されました | B. Riley FBR | Buy |
すべてを表示
Vaxart Inc (VXRT) 最新ニュース
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
RFK Jr. pauses $240 million contract for new ‘oral COVID vaccine’ - Todayville
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates - MSN
Vaxart reports inducement grants under Nasdaq listing rule - TipRanks
Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges - Investing.com
Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges By Investing.com - Investing.com South Africa
Vaxart Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vaxart's Major Talent Investment: 659,500 Share Awards and Key Executive Hire Signals Growth - Stock Titan
B. Riley Cuts Price Target on Vaxart to $2 From $2.50, Keeps Buy Rating - Marketscreener.com
Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call Transcript - Insider Monkey
Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Sudden Trump administration order prompts Bay Area company to lay off staff - SFGATE
Bay Area biotech company lays off staff over sudden Trump admin order - SFGATE
Vaxart Inc to offer up to $50 mln of common stock -March 21, 2025 at 04:42 pm EDT - MarketScreener
RFK Jr. paused this Peninsula company's half-billion-dollar vaccine contract, then it cut jobs - The Business Journals
Vaxart Inc Reports Q4 EPS of -$0.12, Missing Estimates; Revenue at $19.5 Million, Below Expectations - GuruFocus
Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ... - Yahoo Finance
Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments Amid Challenges - GuruFocus.com
Vaxart Reports 2024 Financial Results and Vaccine Progress - TipRanks
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Vaxart, Inc. Investors of Important Deadline in Securities Class Action – VXRT - Business Wire
Earnings call transcript: Vaxart Q4 2024 misses EPS but beats revenue - Investing.com India
Vaxart Inc. (VXRT) reports earnings - Quartz
Vaxart Provides Business Update And Reports Full Year 2024 Financial Results -March 20, 2025 at 04:49 pm EDT - MarketScreener
Vaxart, Inc. SEC 10-K Report - TradingView
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewswire
Vaxart Quadruples Revenue to $28.7M as New Norovirus Vaccine Trial Launches - Stock Titan
Pipeline - Vaxart Inc.
Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20 - GlobeNewswire
Vaxart, Inc. to Host Conference Call for Business Update and Financial Results on March 20, 2025 - Nasdaq
Vaxart's Crucial 2024 Financial Update: Management to Reveal Full-Year Performance - Stock Titan
Vaxart starts early-stage study for its pill-based vaccine for norovirus -March 11, 2025 at 08:57 am EDT - Marketscreener.com
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate - GlobeNewswire
First-Ever Norovirus Pill Vaccine Enters Clinical Trials: Vaxart's Game-Changing Approach - StockTitan
Financial Survey: Quince Therapeutics (NASDAQ:QNCX) & Vaxart (NASDAQ:VXRT) - Defense World
Our Science - Vaxart Inc.
Vaxart's Oral Norovirus Vaccine: Key Study Findings and Future Plans - Contagionlive.com
Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults - The Manila Times
Vaxart (VXRT) Projected to Post Quarterly Earnings on Thursday - Defense World
Vaxart reports promising norovirus vaccine trial results By Investing.com - Investing.com Canada
Vaxart reports promising norovirus vaccine trial results - Investing.com
Vaxart Announces Publication Demonstrating the - GlobeNewswire
Can Vaxart's Oral Norovirus Vaccine Overcome Age-Related Immune Challenges? New Data Says Yes - Stock Titan
Vaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average – Time to Sell? - Defense World
Brother of Biden’s Top Advisor Lobbied for Biotech Firm Awarded COVID Vax Deal Halted by Kennedy - Judicial Watch
RFK Jr. Blocks Plans to Roll Out ‘ORAL Covid Vaccine’ - substack.com
RFK Jr issues bombshell order on Covid vaccine over safety concerns - Daily Mail
Vaxart Inc (VXRT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):